Literature DB >> 7236888

Effect of leukocyte antibodies on the fate in vivo of indium-111-labeled granulocytes.

J McCullough, B J Weiblen, M E Clay, L Forstrom.   

Abstract

The effect of different leukocyte antibodies on the fate in vivo of granulocytes is not known. Thus, the optimum in vitro serologic tests to determine a safe and effective granulocyte transfusion or to diagnose immune destruction of granulocytes in other clinical situations have not been identified. We have studied the effect of granulocyte agglutinating (GA), granulocytotoxic (GC), and lymphocytotoxic (LC) antibodies on the intravascular recovery and half-life (t 1/2) and the extravascular localization of Indium-111-granulocytes in 50 patients. GA antibodies caused reduced granulocyte recovery and t 1/2 in three of three non-neutropenic patients (one with anti-NB1), increased sequestration of cells in the liver, and failure of granulocytes to localize at sites of infection in two of two patients (one with anti-NA1). In contrast, GC antibodies in five patients and LC antibodies in one patient did not cause reduced intravascular recovery or t 1/2 of granulocytes. In nine patients with GC and six patients with LC antibodies, incompatible granulocytes localized at known sites of infection. It appears that GA, but not GC nor LC, antibodies alter the fate in vivo of granulocytes.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7236888

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  3 in total

Review 1.  The use of blood components in patients with malignancy.

Authors:  S Murphy
Journal:  World J Surg       Date:  1987-02       Impact factor: 3.352

Review 2.  The role of neutrophils in the pathogenesis of transfusion-related acute lung injury.

Authors:  Yoke Lin Fung; Christopher C Silliman
Journal:  Transfus Med Rev       Date:  2009-10

3.  Granulocyte transfusions in hematologic malignancy patients with invasive pulmonary aspergillosis: outcomes and complications.

Authors:  I I Raad; A M Chaftari; M M Al Shuaibi; Y Jiang; W Shomali; J E Cortes; B Lichtiger; R Y Hachem
Journal:  Ann Oncol       Date:  2013-03-21       Impact factor: 32.976

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.